NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-Acting Injectable HIV PrEP PROs

Not Yet RecruitingN/A

Sponsor: Anupama Raghuram MD

Conditions: HIV Pre-exposure Prophylaxis

Interventions: Interview and survey to evaluate patient reported outcomes between the two medications.

Countries: United States

The goal of this observational study is to learn about the real world effectiveness, patient satisfaction and clinical outcomes of LAI PrEP with lenacapavir (LEN) versus cabotegravir (CAB) through surveys and interviews. Participants receiving or initiating LAI PrEP part of their regular medical care will complete surveys and interviews at three study visits over the course of 12 months.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Adults aged 18 and older
2. Deemed eligible for HIV PrEP per healthcare provider
3. Receiving or initiating LAI PrEP, defined as:

   1. Current use of CAB or LEN LAI PrEP at study entry
   2. Initiation of either CAB or LEN LAI PrEP within 30 days of study enrollment
4. Receiving PrEP services in Louisville, KY
5. Able to provide informed consent and complete study assessments

Exclusion Criteria:

1. HIV diagnosis prior to enrollment
2. Currently on oral PrEP with no plans to switch to LAI PrEP
3. Hypersensitivities to LEN or CAB
4. Pregnant or planning to become pregnant
5. PI discretion

Locations (3)

Louisville, Kentucky, United States
Louisville, Kentucky, United States
Louisville, Kentucky, United States